AAU-NLP/Lite-BERT-SL
Token Classification
•
Updated
•
21
form_type
stringclasses 2
values | accession_number
stringlengths 20
20
| filing_date
stringlengths 14
14
| quarter_ending
stringclasses 172
values | company_name
stringlengths 5
54
| text
stringlengths 101
2.42k
| entities
listlengths 1
18
|
|---|---|---|---|---|---|---|
10-Q | 0000897101-17-001458 | 20171113161331 | 20170930 | Ben Franklin Financial, Inc. | The Company has incurred losses since 2008 resulting from a combination of: declining net interest income, as our loan portfolio decreased from $109.8 million at December 31, 2008 to $62.3 million at December 31, 2016; increased provisions for loan losses between 2009 and 2012; and increasing non-interest expense related to professional fees and repossessed asset write-downs and costs. The Company recently incurred net losses of $866 for the nine months ended September 30, 2017 and $1,260 during the year ended December 31, 2016. Our interest income for the nine months ended September 30, 2017 has increased with the increase in the balance of our loan portfolio, however, this growth has also resulted in an increase to our provision for loan losses. Our non-interest expense has also increased for compensation and occupancy cost and includes costs for problem asset resolution at the beginning of the year. The loss for 2016 was largely a result of our net interest income reflecting the low balance of our loan portfolio, increasing professional fees for problem asset resolution and additional costs associated with operating as a public company. Non-interest expense for 2016 was also impacted by an operational loss not reimbursable from our insurance. | [
{
"currency_/_unit": "USD",
"end_character": 150,
"end_date_for_period": "2008-12-31",
"label": "XBRL-OOS",
"start_character": 145,
"start_date_for_period": "2008-12-31",
"value": 109800000
},
{
"currency_/_unit": "USD",
"end_character": 188,
"end_date_for_period": "2016-12-31",
"label": "XBRL-OOS",
"start_character": 184,
"start_date_for_period": "2016-12-31",
"value": 62300000
},
{
"currency_/_unit": "USD",
"end_character": 437,
"end_date_for_period": "2017-09-30",
"label": "earnings",
"start_character": 434,
"start_date_for_period": "2017-01-01",
"value": -866000
},
{
"currency_/_unit": "USD",
"end_character": 493,
"end_date_for_period": "2016-12-31",
"label": "earnings",
"start_character": 488,
"start_date_for_period": "2016-01-01",
"value": -1260000
}
] |
10-K | 0000014846-18-000041 | 20181210173253 | 20180930 | BRT Apartments Corp. | Certain items on the consolidated financial statements for the prior years have been reclassified to conform with the current year's presentation, including the reclassification (i) of the operations and related assets of the Newark Joint Venture to discontinued operations, (ii) of deferred loan costs on the consolidated balance sheets from assets to a reduction of the carrying amount of mortgage payable and (iii) tenant utility reimbursements from real estate operating expenses to rental and other revenues from real estate properties. The reclassification of tenant utility reimbursements increased total revenues and expenses by $4,066,000 in 2016, and had no effect on the Company's financial position, results of operation or cash flows. | [
{
"currency_/_unit": "USD",
"end_character": 648,
"end_date_for_period": "2016-09-30",
"label": "revenues",
"start_character": 639,
"start_date_for_period": "2015-10-01",
"value": 4066000
}
] |
10-K | 0000014846-18-000041 | 20181210173253 | 20180930 | BRT Apartments Corp. | (a) Includes Waverly Place, Melbourne FL, sold on October 25, 2017, Valley Venue, Valley, AL, sold on February 23, 2018 and Garden Square, Palm Beach Gardens, FL sold on February 25, 2018. These properties in total had 1,368 units and accounted for $5,815 of 2018 revenues. | [
{
"currency_/_unit": "brt:property_unit",
"end_character": 224,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 219,
"start_date_for_period": "2018-09-30",
"value": 1368
},
{
"currency_/_unit": "USD",
"end_character": 255,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 250,
"start_date_for_period": "2017-10-01",
"value": 5815000
}
] |
10-Q | 0000014846-18-000033 | 20180808164128 | 20180630 | BRT Apartments Corp. | For the three months ended June 30, 2018, no shares were included as their effect would have been anti-dilutive. | [
{
"currency_/_unit": "shares",
"end_character": 44,
"end_date_for_period": "2018-06-30",
"label": "eps",
"start_character": 42,
"start_date_for_period": "2018-04-01",
"value": 0
}
] |
10-Q | 0001084991-18-000049 | 20180809151800 | 20180630 | NATURAL GAS SERVICES GROUP INC | From time to time, upon the customer’s written request, we recognize revenue when manufacturing is complete and the equipment is ready for shipment. At the customer’s request, we will bill the customer upon completing all performance obligations, but before shipment. The customer will formally request we ship the equipment per their direction from our manufacturing facility at a later specified date and that we segregate the equipment from our finished goods, such that they are not available to fill other orders. Per the customer’s agreement change of control is passed to the customer once the equipment is complete and ready for shipment. We have operated using bill and hold agreements with certain customers for many years, with consistent satisfactory results for both the customer and us. The credit terms on these agreements are consistent with the credit terms on all other sales. All control shouldered by the customer, and there are no exceptions to the customer’s commitment to accept and pay for the manufactured equipment. Revenues recognized at the completion of manufacturing for the six months ended June 30, 2018 was approximately $6.3 million. | [
{
"currency_/_unit": "USD",
"end_character": 1158,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 1155,
"start_date_for_period": "2018-01-01",
"value": 6300000
}
] |
10-Q | 0001068875-18-000057 | 20180801064736 | 20180630 | BLUCORA, INC. | As a result of the ASC 606 adoption, the Company now recognizes certain licensing fees on a net basis, which reduced both transaction and fee revenues and operating expenses by $0.4 million and $0.9 million, respectively, for the three and six months ended June 30, 2018, on the consolidated statements of comprehensive income. Had the Company not adopted ASC 606, total revenues for the three and six months ended June 30, 2018 would have been $0.8 million and $2.0 million, respectively, higher than reported on the consolidated statements of comprehensive income. | [
{
"currency_/_unit": "USD",
"end_character": 181,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 178,
"start_date_for_period": "2018-04-01",
"value": -400000
},
{
"currency_/_unit": "USD",
"end_character": 198,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 195,
"start_date_for_period": "2018-01-01",
"value": -900000
},
{
"currency_/_unit": "USD",
"end_character": 449,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 446,
"start_date_for_period": "2018-04-01",
"value": 800000
},
{
"currency_/_unit": "USD",
"end_character": 466,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 463,
"start_date_for_period": "2018-01-01",
"value": 2000000
}
] |
10-Q | 0001610466-18-000069 | 20181102102143 | 20180930 | Shell Midstream Partners, L.P. | Our interest in Amberjack was acquired on May 11, 2018. Amberjack total revenues, total operating expenses and operating income (on a 100% basis) was $214.0 million, $53.8 million and $160.2 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 156,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 151,
"start_date_for_period": "2018-01-01",
"value": 214000000
},
{
"currency_/_unit": "USD",
"end_character": 171,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 167,
"start_date_for_period": "2018-01-01",
"value": 53800000
},
{
"currency_/_unit": "USD",
"end_character": 190,
"end_date_for_period": "2018-09-30",
"label": "ebit",
"start_character": 185,
"start_date_for_period": "2018-01-01",
"value": 160200000
}
] |
10-Q | 0001125345-18-000097 | 20181107160542 | 20180930 | MACROGENICS INC | The Company also has an agreement with Incyte under which the Company is to perform manufacturing services for Incyte’s clinical needs of MGA012. The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the three and nine months ended September 30, 2018, the Company recognized revenue of $6.1 million and $16.0 million, respectively, for services performed under this agreement. | [
{
"currency_/_unit": "USD",
"end_character": 782,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 779,
"start_date_for_period": "2018-07-01",
"value": 6100000
},
{
"currency_/_unit": "USD",
"end_character": 800,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 796,
"start_date_for_period": "2018-07-01",
"value": 16000000
}
] |
10-Q | 0001125345-18-000097 | 20181107160542 | 20180930 | MACROGENICS INC | Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 is being recognized through that date. Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the three and nine months ended September 30, 2018. The Company recognized revenue of $0.5 million and $1.4 million during the three and nine months ended September 30, 2018, respectively, related to the MGD007 option. At September 30, 2018, $0.5 million of revenue related to the MGD007 option was deferred, all of which was current. | [
{
"currency_/_unit": "USD",
"end_character": 1128,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 1125,
"start_date_for_period": "2018-07-01",
"value": 500000
},
{
"currency_/_unit": "USD",
"end_character": 1145,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 1142,
"start_date_for_period": "2018-01-01",
"value": 1400000
},
{
"currency_/_unit": "USD",
"end_character": 1285,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 1282,
"start_date_for_period": "2018-07-01",
"value": 500000
}
] |
10-Q | 0001125345-18-000097 | 20181107160542 | 20180930 | MACROGENICS INC | The Company recognized revenue of $6.1 million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention during May 2018. The warrants are reported in other assets on the balance sheet at September 30, 2018, and there was no material change in the valuation of the warrants from May 2018 through that date. | [
{
"currency_/_unit": "USD",
"end_character": 38,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 35,
"start_date_for_period": "2018-07-01",
"value": 6100000
}
] |
10-Q | 0000930420-18-000276 | 20181101163217 | 20180930 | KFORCE INC | For the three and nine months ended September 30, 2018, there were 635 thousand and 505 thousand common stock equivalents included in the diluted WASO, respectively. For the three and nine months ended September 30, 2017, there were 239 thousand and 301 thousand common stock equivalents included in the diluted WASO, respectively. For the three and nine months ended September 30, 2018 and 2017, there were insignificant anti-dilutive common stock equivalents. | [
{
"currency_/_unit": "shares",
"end_character": 70,
"end_date_for_period": "2018-09-30",
"label": "eps",
"start_character": 67,
"start_date_for_period": "2018-07-01",
"value": 635000
},
{
"currency_/_unit": "shares",
"end_character": 87,
"end_date_for_period": "2018-09-30",
"label": "eps",
"start_character": 84,
"start_date_for_period": "2018-01-01",
"value": 505000
},
{
"currency_/_unit": "shares",
"end_character": 236,
"end_date_for_period": "2017-09-30",
"label": "eps",
"start_character": 233,
"start_date_for_period": "2017-07-01",
"value": 239000
},
{
"currency_/_unit": "shares",
"end_character": 253,
"end_date_for_period": "2017-09-30",
"label": "eps",
"start_character": 250,
"start_date_for_period": "2017-01-01",
"value": 301000
}
] |
10-Q | 0001125920-18-000020 | 20181107172437 | 20180930 | SHUTTERFLY INC | , the Company settled the principal of the convertible senior notes in cash upon their maturity in May 2018. The weighted-average impact to dilution for the period that the conversion option was outstanding was 451,000 shares for the nine months ended September 30, 2018. The potential conversion impact was excluded from the computation of diluted net loss per common share for such periods because including it would have had an anti-dilutive effect. | [
{
"currency_/_unit": "shares",
"end_character": 218,
"end_date_for_period": "2018-09-30",
"label": "eps",
"start_character": 211,
"start_date_for_period": "2018-01-01",
"value": 451000000
}
] |
10-Q | 0001084991-18-000059 | 20181109155024 | 20180930 | NATURAL GAS SERVICES GROUP INC | From time to time, upon the customer’s written request, we recognize revenue when manufacturing is complete and the equipment is ready for shipment. At the customer’s request, we will bill the customer upon completing all performance obligations, but before shipment. The customer will formally request we ship the equipment per their direction from our manufacturing facility at a later specified date and that we segregate the equipment from our finished goods, such that they are not available to fill other orders. Per the customer’s agreement change of control is passed to the customer once the equipment is complete and ready for shipment. We have operated using bill and hold agreements with certain customers for many years, with consistent satisfactory results for both the customer and us. The credit terms on these agreements are consistent with the credit terms on all other sales. All control is shouldered by the customer and there are no exceptions to the customer’s commitment to accept and pay for the manufactured equipment. Revenues recognized related to bill and hold arrangements for the nine months ended September 30, 2018 was approximately $7.6 million. | [
{
"currency_/_unit": "USD",
"end_character": 1169,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 1166,
"start_date_for_period": "2018-01-01",
"value": 7600000
}
] |
10-Q | 0001595974-18-000110 | 20181107184726 | 20180930 | RUBICON PROJECT, INC. | The Company has determined that it does not act as the principal in the purchase and sale of digital advertising inventory because it does not have control of the digital advertising inventory and does not set prices agreed upon within the auction marketplace, and therefore reports revenue on a net basis. In periods prior to the second quarter of 2017, the Company reported revenue on a gross basis for revenue associated with its intent marketing solution, as the Company determined that it acted as the principal in the purchase and sale of digital advertising inventory. The Company ceased offering its intent marketing solution after the first quarter of 2017, after which time, all of the Company’s revenues have been recorded on a net basis. Revenue generated by the Company’s intent marketing solution in 2017 prior to its cessation was $1.3 million, which is included in total revenue for the nine months ended September 30, 2017. | [
{
"currency_/_unit": "USD",
"end_character": 850,
"end_date_for_period": "2017-09-30",
"label": "revenues",
"start_character": 847,
"start_date_for_period": "2017-01-01",
"value": 1300000
}
] |
10-K | 0001336917-19-000011 | 20190222185511 | 20181231 | Under Armour, Inc. | The Company identified an immaterial prior period error in the presentation of premium subscriptions in its Connected Fitness reporting segment. Subscription revenue was previously recorded net of any related commission. Beginning in the first quarter of 2018, subscription revenue is recorded on a gross basis and the related commission cost is included in selling, general and administrative expense in the consolidated statement of operations. The Company has revised the prior periods to be consistent with the current period's presentation resulting in an increase in net revenues and selling, general and administrative expense of $12.7 million and $8.0 million for the years ended December 31, 2017 and 2016, respectively. There was no impact in any period on income (loss) from operations. The Company concluded that the error was not material to any of its previously issued financial statements. | [
{
"currency_/_unit": "USD",
"end_character": 642,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 638,
"start_date_for_period": "2017-01-01",
"value": 12700000
},
{
"currency_/_unit": "USD",
"end_character": 659,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 656,
"start_date_for_period": "2016-01-01",
"value": 8000000
}
] |
10-K | 0001336917-19-000011 | 20190222185511 | 20181231 | Under Armour, Inc. | In addition to the investment in Dome, the Company has a license agreement with Dome. The Company recorded license revenues from Dome of $35.6 million for the year ended December 31, 2018. As of December 31, 2018, the Company has $13.1 million in licensing receivables outstanding, recorded in the prepaid expenses and other current assets line item within the Company's consolidated balance sheet. | [
{
"currency_/_unit": "USD",
"end_character": 142,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 138,
"start_date_for_period": "2018-01-01",
"value": 35600000
},
{
"currency_/_unit": "USD",
"end_character": 235,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 231,
"start_date_for_period": "2018-12-31",
"value": 13100000
}
] |
10-K | 0001336917-19-000011 | 20190222185511 | 20181231 | Under Armour, Inc. | As of December 31, 2018, approximately $165.1 million of cash and cash equivalents was held by the Company's non-U.S. subsidiaries whose cumulative undistributed earnings total $633.6 million. The majority of these earnings were subject to U.S. federal income tax as part of the one-time transition tax on indefinitely reinvested foreign earnings required by the Tax Act. The portion of these earnings not subject to U.S. federal income tax as part of the one-time transition tax should, in general, not be subject to U.S. federal income tax. The Company will continue to permanently reinvest these earnings, as well as future earnings from foreign subsidiaries, to fund international growth and operations. If the Company were to repatriate indefinitely reinvested foreign funds, the Company would be required to accrue and pay any applicable withholding tax and U.S. state income tax liabilities and record foreign exchange rate impacts. Determination of the unrecorded deferred tax liability that would be incurred if such amounts were repatriated is not practicable. | [
{
"currency_/_unit": "USD",
"end_character": 45,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 40,
"start_date_for_period": "2018-12-31",
"value": 165100000
},
{
"currency_/_unit": "USD",
"end_character": 183,
"end_date_for_period": "2018-12-31",
"label": "eps",
"start_character": 178,
"start_date_for_period": "2018-01-01",
"value": 633600000
}
] |
10-K | 0001336917-19-000011 | 20190222185511 | 20181231 | Under Armour, Inc. | Net revenues in the United States were $3,464.0 million, $3,626.6 million, and $3,843.7 million for the years ended December 31, 2018, 2017 and 2016, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 47,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 40,
"start_date_for_period": "2018-01-01",
"value": 3464000000
},
{
"currency_/_unit": "USD",
"end_character": 65,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 58,
"start_date_for_period": "2017-01-01",
"value": 3626600000
},
{
"currency_/_unit": "USD",
"end_character": 87,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 80,
"start_date_for_period": "2016-01-01",
"value": 3843700000
}
] |
10-K | 0001104485-19-000059 | 20190318083501 | 20181231 | NORTHERN OIL & GAS, INC. | As of December 31, 2018, 2017 and 2016, potentially dilutive shares from stock option awards were zero, 250,000 and 391,872, respectively. The Company also has potentially dilutive shares from restricted stock awards outstanding of 2,827,859, 1,721,533, and 1,905,104 at December 31, 2018, 2017 and 2016, respectively. | [
{
"currency_/_unit": "shares",
"end_character": 241,
"end_date_for_period": "2018-12-31",
"label": "eps",
"start_character": 232,
"start_date_for_period": "2018-01-01",
"value": 2827859
},
{
"currency_/_unit": "shares",
"end_character": 252,
"end_date_for_period": "2017-12-31",
"label": "eps",
"start_character": 243,
"start_date_for_period": "2017-01-01",
"value": 1721533
},
{
"currency_/_unit": "shares",
"end_character": 267,
"end_date_for_period": "2016-12-31",
"label": "eps",
"start_character": 258,
"start_date_for_period": "2016-01-01",
"value": 1905104
}
] |
10-K | 0001125345-19-000046 | 20190226161059 | 20181231 | MACROGENICS INC | The Company also has an agreement with Incyte, which was signed in 2018, under which the Company is to perform development and manufacturing services for Incyte’s clinical needs of MGA012. The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement - to perform services related to manufacturing the clinical supply of MGA012. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the year ended December 31, 2018, the Company recognized revenue of $22.2 million for services performed under this agreement. | [
{
"currency_/_unit": "USD",
"end_character": 809,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 805,
"start_date_for_period": "2018-01-01",
"value": 22200000
}
] |
10-K | 0001125345-19-000046 | 20190226161059 | 20181231 | MACROGENICS INC | Revenue associated with each performance obligation is being recognized as the research and development services are provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurs over this time period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation. The full transaction price allocated to flotetuzumab and the third DART molecule was recognized as revenue prior to the adoption of ASC 606 on January 1, 2018 as the option periods had ended. The development period for MGD007 was estimated to be 75 months, ending in December 2018, therefore the transaction price allocated to MGD007 was being recognized through that date. When Servier notified the Company that it was not exercising the option for MGD007 in November 2018, the Company recognized the remaining deferred revenue related to MGD007. Upon the adoption of ASC 606 on January 1, 2018, the pattern of revenue recognition for the upfront fee and the accounting for the milestones received in 2014 changed, but there was no material impact to revenue recognized during the year ended December 31, 2018. During the years ended December 31, 2018, 2017 and 2016 the Company recognized revenue of $1.9 million, $1.1 million and $1.1 million, respectively, related to the MGD007 option. At December 31, 2018, no revenue related to the MGD007 option was deferred. The deferred revenue balance related to the MGD007 option as of December 31, 2017, prior to the adoption of ASC 606, was $1.1 million, all of which was current. | [
{
"currency_/_unit": "USD",
"end_character": 1342,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 1339,
"start_date_for_period": "2018-01-01",
"value": 1900000
},
{
"currency_/_unit": "USD",
"end_character": 1356,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 1353,
"start_date_for_period": "2017-01-01",
"value": 1100000
},
{
"currency_/_unit": "USD",
"end_character": 1373,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 1370,
"start_date_for_period": "2017-01-01",
"value": 1100000
},
{
"currency_/_unit": "USD",
"end_character": 1452,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 1450,
"start_date_for_period": "2018-12-31",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 1630,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 1627,
"start_date_for_period": "2017-01-01",
"value": 1100000
}
] |
10-K | 0001125345-19-000046 | 20190226161059 | 20181231 | MACROGENICS INC | The Company recognized revenue of $6.1 million when it satisfied its performance obligations and transferred the MGD010 license and teplizumab assets to Provention in May 2018. The warrants are reported in other assets on the balance sheet at December 31, 2018 and will be revalued at each reporting period until exercised or the warrants lapse. The Company revalued the warrants based on current Black-Scholes parameters as of December 31, 2018, and recorded a decrease of $4.2 million in other assets. This revaluation is reflected in other income (expense) on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2018. | [
{
"currency_/_unit": "USD",
"end_character": 38,
"end_date_for_period": "2018-05-31",
"label": "revenues",
"start_character": 35,
"start_date_for_period": "2018-05-01",
"value": 6100000
},
{
"currency_/_unit": "USD",
"end_character": 481,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 478,
"start_date_for_period": "2018-01-01",
"value": -4200000
}
] |
10-K | 0001125345-19-000046 | 20190226161059 | 20181231 | MACROGENICS INC | In May 2016, the Company entered into a collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015. The Company received a $75.0 million upfront payment from Janssen upon closing the transaction, which was recognized as revenue in 2016. In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement. No revenue was recognized under the MGD015 Agreement during the year ended December 31, 2018. The Company recognized revenue of $0.6 million and $75.8 million during the years ended December 31, 2017 and 2016, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 598,
"end_date_for_period": "2016-07-31",
"label": "XBRL-OOS",
"start_character": 594,
"start_date_for_period": "2016-07-01",
"value": 75000000
},
{
"currency_/_unit": "USD",
"end_character": 805,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 803,
"start_date_for_period": "2018-01-01",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 935,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 932,
"start_date_for_period": "2017-01-01",
"value": 600000
},
{
"currency_/_unit": "USD",
"end_character": 953,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 949,
"start_date_for_period": "2016-01-01",
"value": 75800000
}
] |
10-K | 0000897101-19-000192 | 20190312110803 | 20181231 | CYBEROPTICS CORP | Revenue from sales of high precision 3D and 2D sensors based on our 3D Multi-Reflection Suppression (MRS) technology was $7.9 million in 2018 and $4.4 million in 2017. Revenue from sales of inspection and metrology systems that incorporate our 3D MRS sensor technology was $13.3 million in 2018 and $10.0 million in 2017. | [
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 122,
"start_date_for_period": "2018-01-01",
"value": 7900000
},
{
"currency_/_unit": "USD",
"end_character": 150,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 147,
"start_date_for_period": "2017-01-01",
"value": 4400000
},
{
"currency_/_unit": "USD",
"end_character": 278,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 274,
"start_date_for_period": "2018-01-01",
"value": 13300000
},
{
"currency_/_unit": "USD",
"end_character": 304,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 300,
"start_date_for_period": "2017-01-01",
"value": 10000000
}
] |
10-K | 0000897101-19-000192 | 20190312110803 | 20181231 | CYBEROPTICS CORP | Revenue from sales of high precision 3D and 2D sensors based on our 3D Multi-Reflection Suppression (MRS) technology was $7.9 million in 2018 and $4.4 million in 2017. Revenue from sales of inspection and metrology systems that incorporate our 3D MRS sensor technology was $13.3 million in 2018 and $10.0 million in 2017. | [
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 122,
"start_date_for_period": "2018-01-01",
"value": 7900000
},
{
"currency_/_unit": "USD",
"end_character": 150,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 147,
"start_date_for_period": "2017-01-01",
"value": 4400000
},
{
"currency_/_unit": "USD",
"end_character": 278,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 274,
"start_date_for_period": "2018-01-01",
"value": 13300000
},
{
"currency_/_unit": "USD",
"end_character": 304,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 300,
"start_date_for_period": "2017-01-01",
"value": 10000000
}
] |
10-K | 0000897101-19-000192 | 20190312110803 | 20181231 | CYBEROPTICS CORP | Revenue from sales of high precision 3D and 2D sensors based on our 3D Multi-Reflection Suppression (MRS) technology was $7.9 million in 2018 and $4.4 million in 2017. Revenue from sales of inspection and metrology systems that incorporate our 3D MRS sensor technology was $13.3 million in 2018 and $10.0 million in 2017. | [
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 122,
"start_date_for_period": "2018-01-01",
"value": 7900000
},
{
"currency_/_unit": "USD",
"end_character": 150,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 147,
"start_date_for_period": "2017-01-01",
"value": 4400000
},
{
"currency_/_unit": "USD",
"end_character": 278,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 274,
"start_date_for_period": "2018-01-01",
"value": 13300000
},
{
"currency_/_unit": "USD",
"end_character": 304,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 300,
"start_date_for_period": "2017-01-01",
"value": 10000000
}
] |
10-K | 0000883945-19-000016 | 20190227171839 | 20181231 | USA TRUCK INC | $41.5 million, $35.5 million, and $36.9 million for the years ended December 31, 2018, 2017 and 2016, respectively. All foreign revenue is collected in U.S. dollars. | [
{
"currency_/_unit": "USD",
"end_character": 5,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 1,
"start_date_for_period": "2018-01-01",
"value": 41500000
},
{
"currency_/_unit": "USD",
"end_character": 20,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 16,
"start_date_for_period": "2017-01-01",
"value": 35500000
},
{
"currency_/_unit": "USD",
"end_character": 39,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 35,
"start_date_for_period": "2016-01-01",
"value": 36900000
}
] |
10-K | 0000883945-19-000016 | 20190227171839 | 20181231 | USA TRUCK INC | , and operations were closed during the first quarter of 2018. Foreign revenue from USAT Logistics de Mexico was $0.8 million and $2.1 million for the years ended December 31, 2018 and 2017, respectively. All foreign revenue is collected in U.S. dollars. | [
{
"currency_/_unit": "USD",
"end_character": 118,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 115,
"start_date_for_period": "2018-01-01",
"value": 800000
},
{
"currency_/_unit": "USD",
"end_character": 135,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 132,
"start_date_for_period": "2017-01-01",
"value": 2100000
}
] |
10-K | 0001628280-19-002785 | 20190311191254 | 20181231 | CUMBERLAND PHARMACEUTICALS INC | The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States. Total revenues are primarily attributable to U.S. customers. Net revenues from customers outside the United States were approximately $2.1 million, $1.6 million and $2.0 million for the years ended December 31, 2018, 2017 and 2016, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 892,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 889,
"start_date_for_period": "2018-01-01",
"value": 2100000
},
{
"currency_/_unit": "USD",
"end_character": 906,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 903,
"start_date_for_period": "2017-01-01",
"value": 1600000
},
{
"currency_/_unit": "USD",
"end_character": 923,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 920,
"start_date_for_period": "2016-01-01",
"value": 2000000
}
] |
10-K | 0001084991-19-000013 | 20190318172718 | 20181231 | NATURAL GAS SERVICES GROUP INC | From time to time, upon the customer’s written request, we recognize revenue when manufacturing is complete and the equipment is ready for shipment. At the customer’s request, we will bill the customer upon completing all performance obligations, but before shipment. The customer will formally request we ship the equipment per their direction from our manufacturing facility at a later specified date and that we segregate the equipment from our finished goods, such that they are not available to fill other orders. Per the customer’s agreement change of control is passed to the customer once the equipment is complete and ready for shipment. We have operated using bill and hold agreements with certain customers for many years, with consistent satisfactory results for both the customer and us. The credit terms on these agreements are consistent with the credit terms on all other sales. All control is shouldered by the customer and there are no exceptions to the customer’s commitment to accept and pay for the manufactured equipment. Revenues recognized related to bill and hold arrangements for the years ended December 31, 2018 and 2017 was approximately $8.3 million and $4.6 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 1171,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 1168,
"start_date_for_period": "2018-01-01",
"value": 8300000.000000001
},
{
"currency_/_unit": "USD",
"end_character": 1188,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 1185,
"start_date_for_period": "2017-01-01",
"value": 4600000
}
] |
10-K | 0001439222-19-000004 | 20190214084837 | 20181231 | AGIOS PHARMACEUTICALS INC | During the year ended December 31, 2018, we recognized $0.2 million as collaboration revenue - other for certain other services provided by us, that were not considered performance obligations as of the inception date of the CStone Agreement. | [
{
"currency_/_unit": "USD",
"end_character": 59,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 56,
"start_date_for_period": "2018-01-01",
"value": 200000
}
] |
10-K | 0001628280-19-002990 | 20190315114104 | 20181231 | WillScot Corp | (c) Historic Acton revenues were $93.9 million and historic ModSpace revenues were $443.5 million, respectively, for the year ended December 31, 2017. Historic Acton pre-tax loss was $3.2 million and historic ModSpace pre-tax loss was $108.1 million, respectively, for the year ended December 31, 2017. | [
{
"currency_/_unit": "USD",
"end_character": 38,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 34,
"start_date_for_period": "2017-01-01",
"value": 93900000
},
{
"currency_/_unit": "USD",
"end_character": 89,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 84,
"start_date_for_period": "2017-01-01",
"value": 443500000
},
{
"currency_/_unit": "USD",
"end_character": 187,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 184,
"start_date_for_period": "2017-01-01",
"value": 3200000
},
{
"currency_/_unit": "USD",
"end_character": 241,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 236,
"start_date_for_period": "2017-01-01",
"value": 108100000
}
] |
10-K | 0001628280-19-002990 | 20190315114104 | 20181231 | WillScot Corp | (e) Depreciation of rental equipment and non-rental depreciation were adjusted for the fair value mark-ups of equipment acquired in the Acton and ModSpace acquisitions. For the year ended December 31, 2017, Acton had additional depreciation expense of $5.3 million and ModSpace had a reduction of $18.9 million. | [
{
"currency_/_unit": "USD",
"end_character": 256,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 253,
"start_date_for_period": "2017-01-01",
"value": 5300000
},
{
"currency_/_unit": "USD",
"end_character": 302,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 298,
"start_date_for_period": "2017-01-01",
"value": -18900000
}
] |
10-K | 0001628280-19-002990 | 20190315114104 | 20181231 | WillScot Corp | (i) Interest on Acton and ModSpace historic debt was eliminated. Historic Acton interest was $5.1 million and historic ModSpace interest was $40.4 million, respectively, for the year ended December 31, 2017. | [
{
"currency_/_unit": "USD",
"end_character": 97,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 94,
"start_date_for_period": "2017-01-01",
"value": 5100000
},
{
"currency_/_unit": "USD",
"end_character": 146,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 142,
"start_date_for_period": "2017-01-01",
"value": 40400000
}
] |
10-K | 0001714973-19-000013 | 20190219070525 | 20181231 | Kinder Morgan Canada Ltd | Income from continuing operations before income taxes for years ended December 31, 2018, 2017, and 2016 were $137.8 million, $71.3 million, and $93.8 million, respectively. | [
{
"currency_/_unit": "CAD",
"end_character": 115,
"end_date_for_period": "2018-12-31",
"label": "earnings",
"start_character": 110,
"start_date_for_period": "2018-01-01",
"value": 137800000
},
{
"currency_/_unit": "CAD",
"end_character": 130,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 126,
"start_date_for_period": "2017-01-01",
"value": 71300000
},
{
"currency_/_unit": "CAD",
"end_character": 149,
"end_date_for_period": "2016-12-31",
"label": "earnings",
"start_character": 145,
"start_date_for_period": "2016-01-01",
"value": 93800000
}
] |
10-K | 0001654948-19-000025 | 20190416170051 | 20181231 | Hartman vREIT XXI, Inc. | For the years ended December 31, 2018 and 2017, we incurred a net loss of $1,292,229 and $1,537,566, respectively. We do not anticipate forming any taxable REIT subsidiaries or otherwise generating future taxable income which may be offset by the net loss carry forward. We consider that any deferred tax benefit and corresponding deferred tax asset which may be recorded in light of the net loss carry forward would be properly offset by an equal valuation allowance in that no future taxable income is expected. Accordingly, no deferred tax benefit or deferred tax asset has been recorded in the consolidated financial statements. | [
{
"currency_/_unit": "USD",
"end_character": 84,
"end_date_for_period": "2018-12-31",
"label": "earnings",
"start_character": 75,
"start_date_for_period": "2018-01-01",
"value": -1292229
},
{
"currency_/_unit": "USD",
"end_character": 99,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 90,
"start_date_for_period": "2017-01-01",
"value": -1537566
}
] |
10-K | 0001654948-19-000025 | 20190416170051 | 20181231 | Hartman vREIT XXI, Inc. | The primary source of our revenue is rental revenues and tenant reimbursements. Total revenue for the year ended December 31, 2018 was $1,550,246, an increase of approximately $632,000 over the year ended December 31, 2017. The increase is attributable to our ownership of Richardson Tech Center beginning in March, 2018 and nominally to our acquisition of the Spectrum Building late in December, 2018. | [
{
"currency_/_unit": "USD",
"end_character": 146,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 137,
"start_date_for_period": "2018-01-01",
"value": 1550246
}
] |
10-K | 0001654948-19-000025 | 20190416170051 | 20181231 | Hartman vREIT XXI, Inc. | For the years ended December 31, 2018 and 2017, the Company incurred a net loss of $1,292,229 and $1,537,566, respectively. The Company does not anticipate forming any taxable REIT subsidiaries or otherwise generating future taxable income which may be offset by the net loss carry forward. The Company considers that any deferred tax benefit and corresponding deferred tax asset which may be recorded in light of the net loss carry forward would be properly offset by an equal valuation allowance in that no future taxable income is expected. Accordingly, no deferred tax benefit or deferred tax asset has been recorded in the consolidated financial statements. | [
{
"currency_/_unit": "USD",
"end_character": 93,
"end_date_for_period": "2018-12-31",
"label": "earnings",
"start_character": 84,
"start_date_for_period": "2018-01-01",
"value": -1292229
},
{
"currency_/_unit": "USD",
"end_character": 108,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 99,
"start_date_for_period": "2017-01-01",
"value": -1537566
}
] |
10-K | 0001654948-19-000025 | 20190416170051 | 20181231 | Hartman vREIT XXI, Inc. | For the years ended December 31, 2018 and 2017, the Company had net loss of $1,292,229 and $1,537,566, respectively. The Company does not anticipate forming any taxable REIT subsidiaries or otherwise generating future taxable income which may be offset by the net loss carry forward. The Company considers that any deferred tax benefit and corresponding deferred tax asset which may be recorded in light of the net loss carry forward would be properly offset by an equal valuation allowance in that no future taxable income is expected. Accordingly, no deferred tax benefit or deferred tax asset has been recorded in the consolidated financial statements. | [
{
"currency_/_unit": "USD",
"end_character": 86,
"end_date_for_period": "2018-12-31",
"label": "earnings",
"start_character": 77,
"start_date_for_period": "2018-01-01",
"value": -1292229
},
{
"currency_/_unit": "USD",
"end_character": 101,
"end_date_for_period": "2017-12-31",
"label": "earnings",
"start_character": 92,
"start_date_for_period": "2017-01-01",
"value": -1537566
}
] |
10-K | 0001628280-19-003719 | 20190401160610 | 20181231 | Teligent, Inc. | For the year ended December 31, 2018, domestic net revenues were $45.6 million and foreign net revenues were $20.2 million. As of December 31, 2018, domestic assets were $132.7 million and foreign assets were $58.2 million. For the year ended December 31, 2017, domestic net revenues were $47.0 million and foreign net revenues were $13.2 million. As of December 31, 2017, domestic assets were $112.6 million and foreign assets were $72.0 million. For the year ended December 31, 2016, domestic net revenues were $52.8 million and foreign net revenues were $10.2 million. | [
{
"currency_/_unit": "USD",
"end_character": 70,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 66,
"start_date_for_period": "2018-01-01",
"value": 45600000
},
{
"currency_/_unit": "USD",
"end_character": 114,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 110,
"start_date_for_period": "2018-01-01",
"value": 20200000
},
{
"currency_/_unit": "USD",
"end_character": 176,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 171,
"start_date_for_period": "2018-12-31",
"value": 132699999.99999999
},
{
"currency_/_unit": "USD",
"end_character": 214,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 210,
"start_date_for_period": "2018-12-31",
"value": 58200000
},
{
"currency_/_unit": "USD",
"end_character": 294,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 290,
"start_date_for_period": "2017-01-01",
"value": 47000000
},
{
"currency_/_unit": "USD",
"end_character": 338,
"end_date_for_period": "2017-12-31",
"label": "revenues",
"start_character": 334,
"start_date_for_period": "2017-01-01",
"value": 13200000
},
{
"currency_/_unit": "USD",
"end_character": 400,
"end_date_for_period": "2017-12-31",
"label": "XBRL-OOS",
"start_character": 395,
"start_date_for_period": "2017-12-31",
"value": 112600000
},
{
"currency_/_unit": "USD",
"end_character": 438,
"end_date_for_period": "2017-12-31",
"label": "XBRL-OOS",
"start_character": 434,
"start_date_for_period": "2017-12-31",
"value": 72000000
},
{
"currency_/_unit": "USD",
"end_character": 518,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 514,
"start_date_for_period": "2016-01-01",
"value": 52800000
},
{
"currency_/_unit": "USD",
"end_character": 562,
"end_date_for_period": "2016-12-31",
"label": "revenues",
"start_character": 558,
"start_date_for_period": "2016-01-01",
"value": 10200000
}
] |
10-K | 0000812128-19-000017 | 20191219073407 | 20191031 | SANDERSON FARMS INC | Sales of offal are considered by-products; accordingly, these amounts reduce cost of sales and totaled $31.1 million, $34.4 million and $32.6 million in fiscal 2019, 2018 and 2017, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 108,
"end_date_for_period": "2019-10-31",
"label": "revenues",
"start_character": 104,
"start_date_for_period": "2018-11-01",
"value": 31100000
},
{
"currency_/_unit": "USD",
"end_character": 123,
"end_date_for_period": "2018-10-31",
"label": "revenues",
"start_character": 119,
"start_date_for_period": "2017-11-01",
"value": 34400000
},
{
"currency_/_unit": "USD",
"end_character": 141,
"end_date_for_period": "2017-10-31",
"label": "revenues",
"start_character": 137,
"start_date_for_period": "2016-11-01",
"value": 32600000
}
] |
10-K | 0000812128-19-000017 | 20191219073407 | 20191031 | SANDERSON FARMS INC | The Company sells certain of its products either directly to foreign markets or to U.S. based customers who resell the product in foreign markets. These foreign markets for fiscal 2019 and 2018 were primarily Mexico, Cuba, Central Asia and the Middle East, and for fiscal 2017 were primarily Mexico, Central Asia and the Middle East. These export sales for fiscal years 2019, 2018 and 2017 totaled approximately $284.5 million, $215.8 million and $268.5 million, respectively. The Company does not believe that the amount of sales attributable to any single foreign country is material to its total sales during any of the periods presented. The Company’s export sales are facilitated through independent food brokers located in the United States and the Company’s internal sales staff. | [
{
"currency_/_unit": "USD",
"end_character": 418,
"end_date_for_period": "2019-10-31",
"label": "revenues",
"start_character": 413,
"start_date_for_period": "2018-11-01",
"value": 284500000
},
{
"currency_/_unit": "USD",
"end_character": 434,
"end_date_for_period": "2018-10-31",
"label": "revenues",
"start_character": 429,
"start_date_for_period": "2017-11-01",
"value": 215800000
},
{
"currency_/_unit": "USD",
"end_character": 453,
"end_date_for_period": "2017-10-31",
"label": "revenues",
"start_character": 448,
"start_date_for_period": "2016-11-01",
"value": 268500000
}
] |
10-K | 0000350797-19-000065 | 20191220173027 | 20191031 | EATON VANCE CORP | 17.0 million for the years ended October 31, 2018 and 2017, respectively. Lastly, contingent deferred sales charges received, which were previously recorded as a reduction of deferred sales commission assets, are now recorded as revenue within the distribution and underwriting fees line item in the Consolidated Statements of Income. | [
{
"currency_/_unit": "USD",
"end_character": 4,
"end_date_for_period": "2017-10-31",
"label": "revenues",
"start_character": 0,
"start_date_for_period": "2016-11-01",
"value": 17000000
}
] |
10-Q | 0000014846-19-000021 | 20190509150919 | 20190331 | BRT Apartments Corp. | Basic earnings (loss) per share is determined by dividing net income (loss) applicable to common stockholders for the applicable period by the weighted average number of shares of common stock outstanding during such period. The Units are excluded from the basic earnings per share calculation, as they are not participating securities. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into shares of common stock or resulted in the issuance of shares of common stock that share in the earnings of the Company. Diluted earnings per share is determined by dividing net income applicable to common stockholders for the applicable period by the weighted average number of shares of common stock deemed to be outstanding during such period. In calculating diluted earnings per share, the Company, for the three months ended (i) March 31, 2019, did not include any shares underlying the Units as their effect would have been anti-dilutive and (ii) March 31, 2018, included 200,000 | [
{
"currency_/_unit": "shares",
"end_character": 1086,
"end_date_for_period": "2018-03-31",
"label": "eps",
"start_character": 1079,
"start_date_for_period": "2018-01-01",
"value": 200000
}
] |
10-Q | 0001277902-19-000024 | 20190501160902 | 20190331 | MVB FINANCIAL CORP | For the three months ended March 31, 2019, the Commercial & Retail Banking segment earned $4.2 million compared to $3.6 million in 2018. Net interest income increased by $2.4 million, primarily the result of an increase of $4.3 million in interest and fees on loans | [
{
"currency_/_unit": "USD",
"end_character": 94,
"end_date_for_period": "2019-03-31",
"label": "earnings",
"start_character": 91,
"start_date_for_period": "2019-01-01",
"value": 4200000
},
{
"currency_/_unit": "USD",
"end_character": 119,
"end_date_for_period": "2018-03-31",
"label": "earnings",
"start_character": 116,
"start_date_for_period": "2018-01-01",
"value": 3600000
},
{
"currency_/_unit": "USD",
"end_character": 174,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 171,
"start_date_for_period": "2019-01-01",
"value": 2400000
},
{
"currency_/_unit": "USD",
"end_character": 227,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 224,
"start_date_for_period": "2019-01-01",
"value": 4300000
}
] |
10-Q | 0001277902-19-000024 | 20190501160902 | 20190331 | MVB FINANCIAL CORP | For the three months ended March 31, 2019, the Mortgage Banking segment earned $335 thousand compared to $150 thousand in 2018. Net interest income decreased $63 thousand, which was the result of | [
{
"currency_/_unit": "USD",
"end_character": 83,
"end_date_for_period": "2019-03-31",
"label": "earnings",
"start_character": 80,
"start_date_for_period": "2019-01-01",
"value": 335000
},
{
"currency_/_unit": "USD",
"end_character": 109,
"end_date_for_period": "2018-03-31",
"label": "earnings",
"start_character": 106,
"start_date_for_period": "2018-01-01",
"value": 150000
},
{
"currency_/_unit": "USD",
"end_character": 161,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 159,
"start_date_for_period": "2019-01-01",
"value": -63000
}
] |
10-Q | 0001084991-19-000033 | 20190510122647 | 20190510 | NATURAL GAS SERVICES GROUP INC | From time to time, upon the customer’s written request, we recognize revenue when manufacturing is complete and the equipment is ready for shipment. At the customer’s request, we will bill the customer upon completing all performance obligations, but before shipment. The customer will formally request we ship the equipment per their direction from our manufacturing facility at a later specified date and that we segregate the equipment from our finished goods, such that they are not available to fill other orders. Per the customer’s agreement change of control is passed to the customer once the equipment is complete and ready for shipment. We have operated using bill and hold agreements with certain customers for many years, with consistent satisfactory results for both the customer and us. The credit terms on these agreements are consistent with the credit terms on all other sales. All control is shouldered by the customer and there are no exceptions to the customer’s commitment to accept and pay for the manufactured equipment. Revenues recognized related to bill and hold arrangements for the three months ended March 31, 2019 was approximately $2.7 million. | [
{
"currency_/_unit": "USD",
"end_character": 1166,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 1163,
"start_date_for_period": "2019-01-01",
"value": 2700000
}
] |
10-Q | 0001336917-19-000037 | 20190509154227 | 20190331 | Under Armour, Inc. | In addition to the investment in Dome, the Company has a license agreement with Dome. The Company recorded license revenues from Dome of $6.5 million for the three months ended March 31, 2019. As of March 31, 2019 | [
{
"currency_/_unit": "USD",
"end_character": 141,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 138,
"start_date_for_period": "2019-01-01",
"value": 6500000
}
] |
10-Q | 0001735828-19-000024 | 20190510160423 | 20190331 | Legacy Reserves Inc. | For the period ended March 31, 2019 and 2018 we recorded income/(loss) before income taxes of $(78,378) and $64,869. respectively. All of Legacy's income is sourced within the United States. The effective combined U.S. federal and state income tax rates were 0% and 0.75% for the three months ended March 31, 2019 and 2018, respectively. During the three months ended March 31, 2019, the Legacy Inc. has recorded a full valuation allowance against its deferred tax position. A valuation allowance has been recorded as management does not believe that it is more-likely-than-not that its deferred tax assets will be realized. | [
{
"currency_/_unit": "USD",
"end_character": 102,
"end_date_for_period": "2019-03-31",
"label": "earnings",
"start_character": 96,
"start_date_for_period": "2019-01-01",
"value": -78378000
},
{
"currency_/_unit": "USD",
"end_character": 115,
"end_date_for_period": "2018-03-31",
"label": "earnings",
"start_character": 109,
"start_date_for_period": "2018-01-01",
"value": 64869000
},
{
"currency_/_unit": "pure",
"end_character": 260,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 259,
"start_date_for_period": "2019-01-01",
"value": 0
},
{
"currency_/_unit": "pure",
"end_character": 270,
"end_date_for_period": "2018-03-31",
"label": "XBRL-OOS",
"start_character": 266,
"start_date_for_period": "2018-01-01",
"value": 0.007500000000000001
}
] |
10-Q | 0001125345-19-000059 | 20190501160614 | 20190331 | MACROGENICS INC | The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte’s clinical needs of MGA012. The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the clinical supply of MGA012. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the three months ended March 31, 2019, the Company recognized revenue of $4.0 million for services performed under this agreement. No revenue was recognized during the three months ended March 31, 2018 for services performed under this agreement. | [
{
"currency_/_unit": "USD",
"end_character": 817,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 814,
"start_date_for_period": "2019-01-01",
"value": 4000000
},
{
"currency_/_unit": "USD",
"end_character": 873,
"end_date_for_period": "2018-03-31",
"label": "revenues",
"start_character": 871,
"start_date_for_period": "2018-01-01",
"value": 0
}
] |
10-Q | 0001125345-19-000059 | 20190501160614 | 20190331 | MACROGENICS INC | Revenue associated with each performance obligation was recognized as the research and development services were provided using an input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management’s judgment, was the best measure of progress towards satisfying the performance obligation. All revenue related to the upfront payment was recognized by December 31, 2018. The Company recognized no revenue during the three months ended March 31, 2019 related to the upfront payment and recognized $0.5 million in revenue during the three months ended March 31, 2018 related to the transaction price allocated to the MGD007 option. No revenue was deferred at December 31, 2018 or March 31, 2019. | [
{
"currency_/_unit": "USD",
"end_character": 538,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 536,
"start_date_for_period": "2019-01-01",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 642,
"end_date_for_period": "2018-03-31",
"label": "revenues",
"start_character": 639,
"start_date_for_period": "2018-01-01",
"value": 500000
}
] |
10-Q | 0001125345-19-000059 | 20190501160614 | 20190331 | MACROGENICS INC | Due to the relatively short-term nature of the recognition period, the revenue associated with the MGD013 performance obligation is being recognized on a straight-line basis as the Company performs research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements. During the three months ended March 31, 2019, the Company recognized revenue of $4.0 million related to the Zai Lab Agreement. At March 31, 2019, $17.1 million of revenue was deferred under this | [
{
"currency_/_unit": "USD",
"end_character": 837,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 834,
"start_date_for_period": "2019-01-01",
"value": 4000000
},
{
"currency_/_unit": "USD",
"end_character": 905,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 901,
"start_date_for_period": "2019-03-31",
"value": 17100000
}
] |
10-Q | 0000930420-19-000122 | 20190502163725 | 20190331 | KFORCE INC | For the three months ended March 31, 2019 and 2018, there were 503 thousand and 290 thousand common stock equivalents included in the diluted WASO, respectively. For the three months ended March 31, 2019 and 2018, there were insignificant anti-dilutive common stock equivalents. | [
{
"currency_/_unit": "shares",
"end_character": 66,
"end_date_for_period": "2019-03-31",
"label": "eps",
"start_character": 63,
"start_date_for_period": "2019-01-01",
"value": 503000
},
{
"currency_/_unit": "shares",
"end_character": 83,
"end_date_for_period": "2018-03-31",
"label": "eps",
"start_character": 80,
"start_date_for_period": "2018-01-01",
"value": 290000
}
] |
10-Q | 0001628280-19-005793 | 20190503111828 | 20190331 | WillScot Corp | Includes $3.8 million and $2.3 million of VAPS service revenue for the three months ended March 31, 2019 and 2018, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 13,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 10,
"start_date_for_period": "2019-01-01",
"value": 3800000
},
{
"currency_/_unit": "USD",
"end_character": 30,
"end_date_for_period": "2018-03-31",
"label": "revenues",
"start_character": 27,
"start_date_for_period": "2018-01-01",
"value": 2300000
}
] |
10-Q | 0001628280-19-006554 | 20190510160514 | 20190331 | Teligent, Inc. | For the three months ended March 31, 2019, domestic net revenues were $9.7 million and foreign net revenues were $3.4 million. As of March 31, 2019, domestic assets were $135.5 million and foreign assets were $56.4 million. For the three months ended March 31, 2018, domestic net revenues were $10.2 million and foreign net revenues were | [
{
"currency_/_unit": "USD",
"end_character": 74,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 71,
"start_date_for_period": "2019-01-01",
"value": 9700000
},
{
"currency_/_unit": "USD",
"end_character": 117,
"end_date_for_period": "2019-03-31",
"label": "revenues",
"start_character": 114,
"start_date_for_period": "2019-01-01",
"value": 3400000
},
{
"currency_/_unit": "USD",
"end_character": 176,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 171,
"start_date_for_period": "2019-03-31",
"value": 135500000
},
{
"currency_/_unit": "USD",
"end_character": 214,
"end_date_for_period": "2019-03-31",
"label": "XBRL-OOS",
"start_character": 210,
"start_date_for_period": "2019-03-31",
"value": 56400000
},
{
"currency_/_unit": "USD",
"end_character": 299,
"end_date_for_period": "2018-03-31",
"label": "revenues",
"start_character": 295,
"start_date_for_period": "2018-01-01",
"value": 10200000
}
] |
10-Q | 0000930420-19-000176 | 20190801161138 | 20190630 | KFORCE INC | For the three and six months ended June 30, 2019, 557 thousand and 538 thousand common stock equivalents were included in the diluted WASO, respectively. For the three and six months ended June 30, 2018, 473 thousand and 398 thousand common stock equivalents were included in the diluted WASO, respectively. For the three and six months ended June 30, 2019 and 2018, there were insignificant anti-dilutive common stock equivalents. | [
{
"currency_/_unit": "shares",
"end_character": 53,
"end_date_for_period": "2019-06-30",
"label": "eps",
"start_character": 50,
"start_date_for_period": "2019-04-01",
"value": 557000
},
{
"currency_/_unit": "shares",
"end_character": 70,
"end_date_for_period": "2019-06-30",
"label": "eps",
"start_character": 67,
"start_date_for_period": "2019-01-01",
"value": 538000
},
{
"currency_/_unit": "shares",
"end_character": 207,
"end_date_for_period": "2018-06-30",
"label": "eps",
"start_character": 204,
"start_date_for_period": "2018-04-01",
"value": 473000
},
{
"currency_/_unit": "shares",
"end_character": 224,
"end_date_for_period": "2018-06-30",
"label": "eps",
"start_character": 221,
"start_date_for_period": "2018-01-01",
"value": 398000
}
] |
10-Q | 0000014846-19-000031 | 20190808150948 | 20190630 | BRT Apartments Corp. | Basic earnings (loss) per share is determined by dividing net income (loss) applicable to common stockholders for the applicable period by the weighted average number of shares of common stock outstanding during such period. The Units are excluded from the basic earnings per share calculation, as they are not participating securities. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into shares of common stock or resulted in the issuance of shares of common stock that share in the earnings of the Company. Diluted earnings per share is determined by dividing net income applicable to common stockholders for the applicable period by the weighted average number of shares of common stock deemed to be outstanding during such period. In calculating diluted earnings per share, the Company, for the three and six months ended June 30, 2019 and the three months ended June 30, 2018, did not include any shares underlying the Units as their effect would have been anti-dilutive. For the six months ended June 30, 2018, the Company included 200,000 | [
{
"currency_/_unit": "shares",
"end_character": 1159,
"end_date_for_period": "2018-06-30",
"label": "eps",
"start_character": 1152,
"start_date_for_period": "2018-01-01",
"value": 200000
}
] |
10-Q | 0001564590-19-028387 | 20190802162147 | 20190630 | NAVIGANT CONSULTING INC | Managed services revenue for the three and six months ended June 30, 2019 was $60.6 million and $117.4 million, respectively and was $31.9 million and $63.3 million for the three and six months ended June 30, 2018. Managed services made up 31% of total revenue before reimbursements for both the three and six months ended June 30, 2019, and 19% for both the three and six months ended June 30, 2018. | [
{
"currency_/_unit": "USD",
"end_character": 83,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 79,
"start_date_for_period": "2019-04-01",
"value": 60600000
},
{
"currency_/_unit": "USD",
"end_character": 102,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 97,
"start_date_for_period": "2019-01-01",
"value": 117400000
},
{
"currency_/_unit": "USD",
"end_character": 138,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 134,
"start_date_for_period": "2018-04-01",
"value": 31900000
},
{
"currency_/_unit": "USD",
"end_character": 156,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 152,
"start_date_for_period": "2018-01-01",
"value": 63300000
}
] |
10-Q | 0001104506-19-000020 | 20190801073323 | 20190630 | INSMED Inc | The Company had $601.3 million in cash and cash equivalents as of June 30, 2019 and reported a net loss of $140.7 million for the six months ended June 30, 2019. Historically, the Company has funded its operations through public offerings of equity securities and debt financings. The Company commenced commercial shipments of ARIKAYCE in October 2018. The Company expects to continue to incur operating losses both at our US and certain international entities while funding research and development (R&D) activities for ARIKAYCE and our other pipeline programs, continuing commercial launch activities for ARIKAYCE in the US, continuing to invest in pre-commercial and regulatory activities for ARIKAYCE in Europe and Japan, and funding other general and administrative activities. The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop INS1007 and INS1009 and to develop, acquire, in-license or co-promote other products or product candidates that address orphan or rare diseases. | [
{
"currency_/_unit": "USD",
"end_character": 22,
"end_date_for_period": "2019-06-30",
"label": "XBRL-OOS",
"start_character": 17,
"start_date_for_period": "2019-06-30",
"value": 601300000
},
{
"currency_/_unit": "USD",
"end_character": 113,
"end_date_for_period": "2019-06-30",
"label": "earnings",
"start_character": 108,
"start_date_for_period": "2019-01-01",
"value": -140700000
}
] |
10-Q | 0000350797-19-000036 | 20190906151630 | 20190731 | EATON VANCE CORP | 13.4 million for the three and nine months ended July 31, 2018, respectively, as a result of this change. Lastly, contingent deferred sales charges received, which were previously recorded as a reduction of deferred sales commission assets, are now being recorded as revenue within the distribution and underwriting fees line item in the Consolidated Statements of Income. | [
{
"currency_/_unit": "USD",
"end_character": 4,
"end_date_for_period": "2018-07-31",
"label": "revenues",
"start_character": 0,
"start_date_for_period": "2017-11-01",
"value": 13400000
}
] |
10-Q | 0001735828-19-000029 | 20190809082130 | 20190630 | Legacy Reserves Inc. | For the six months ended June 30, 2019 and 2018 we recorded income/(loss) before income taxes of $(141,148) and $14,290 respectively. All of Legacy's income is sourced within the United States. The effective combined U.S. federal and state income tax rates were 0.00% and 4.30% for the six months ended June 30, 2019 and 2018, respectively. During the six months ended June 30, 2019, the Legacy Inc. has recorded a full valuation allowance against its deferred tax position. A valuation allowance has been recorded as management does not believe that it is more-likely-than-not that its deferred tax assets will be realized. | [
{
"currency_/_unit": "USD",
"end_character": 106,
"end_date_for_period": "2019-06-30",
"label": "earnings",
"start_character": 99,
"start_date_for_period": "2019-01-01",
"value": -141148000
},
{
"currency_/_unit": "USD",
"end_character": 119,
"end_date_for_period": "2018-06-30",
"label": "earnings",
"start_character": 113,
"start_date_for_period": "2018-01-01",
"value": 14290000
},
{
"currency_/_unit": "pure",
"end_character": 266,
"end_date_for_period": "2019-06-30",
"label": "XBRL-OOS",
"start_character": 262,
"start_date_for_period": "2019-01-01",
"value": 0
},
{
"currency_/_unit": "pure",
"end_character": 276,
"end_date_for_period": "2018-06-30",
"label": "XBRL-OOS",
"start_character": 272,
"start_date_for_period": "2018-01-01",
"value": 0.043000000000000003
}
] |
10-Q | 0001171200-19-000278 | 20190726150523 | 20190630 | ROLLINS INC | Clark Pest
Control has a customer base of approximately 145,000 customers, which are served from 26 service locations in 2 states. Clark
Pest Control recorded revenues of approximately $139.2 million for the fiscal year ended December 31, 2018. This acquisition
will broaden Rollins' market share considerably. The Company's consolidated statements of income include the results of
operations of Clark Pest Control for the period beginning April 30, 2019 through June 30, 2019. | [
{
"currency_/_unit": "USD",
"end_character": 191,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 186,
"start_date_for_period": "2018-01-01",
"value": 139200000
}
] |
10-Q | 0001486159-19-000032 | 20190809114034 | 20190630 | Oasis Petroleum Inc. | The Company’s effective tax rate for the three and six months ended June 30, 2019 was 19.3% on a pre-tax income of $63.4 million and (17.7)% on a pre-tax loss of $48.3 million, respectively, as compared to an effective tax rate of 24.2% on a pre-tax loss of $417.3 million and 24.3% on a pre-tax loss of $412.8 million for the three and six months ended June 30, 2018, respectively. | [
{
"currency_/_unit": "pure",
"end_character": 90,
"end_date_for_period": "2019-06-30",
"label": "XBRL-OOS",
"start_character": 86,
"start_date_for_period": "2019-04-01",
"value": 0.193
},
{
"currency_/_unit": "USD",
"end_character": 120,
"end_date_for_period": "2019-06-30",
"label": "earnings",
"start_character": 116,
"start_date_for_period": "2019-04-01",
"value": 63400000
},
{
"currency_/_unit": "pure",
"end_character": 138,
"end_date_for_period": "2019-06-30",
"label": "XBRL-OOS",
"start_character": 134,
"start_date_for_period": "2019-01-01",
"value": -0.177
},
{
"currency_/_unit": "USD",
"end_character": 167,
"end_date_for_period": "2019-06-30",
"label": "earnings",
"start_character": 163,
"start_date_for_period": "2019-01-01",
"value": -48300000
},
{
"currency_/_unit": "pure",
"end_character": 235,
"end_date_for_period": "2018-06-30",
"label": "XBRL-OOS",
"start_character": 231,
"start_date_for_period": "2018-04-01",
"value": 0.242
},
{
"currency_/_unit": "USD",
"end_character": 264,
"end_date_for_period": "2018-06-30",
"label": "earnings",
"start_character": 259,
"start_date_for_period": "2018-04-01",
"value": -417300000
},
{
"currency_/_unit": "pure",
"end_character": 281,
"end_date_for_period": "2018-06-30",
"label": "XBRL-OOS",
"start_character": 277,
"start_date_for_period": "2018-01-01",
"value": 0.243
},
{
"currency_/_unit": "USD",
"end_character": 310,
"end_date_for_period": "2018-06-30",
"label": "earnings",
"start_character": 305,
"start_date_for_period": "2018-01-01",
"value": -412800000
}
] |
10-Q | 0000109380-19-000179 | 20190806171145 | 20190630 | ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ | The Bank enters into certain lease agreements where it is the lessor of real estate. Real estate leases are made from bank-owned and subleased property to generate cash flow from the property, including from leasing vacant suites in which the Bank occupies portions of the building. Operating lease income was $3 million for both the second quarters of 2019 and 2018, and $6 million and $5 million for the first six months of 2019 and 2018. | [
{
"currency_/_unit": "USD",
"end_character": 312,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 311,
"start_date_for_period": "2019-04-01",
"value": 3000000
},
{
"currency_/_unit": "USD",
"end_character": 374,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 373,
"start_date_for_period": "2019-01-01",
"value": 6000000
},
{
"currency_/_unit": "USD",
"end_character": 389,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 388,
"start_date_for_period": "2018-01-01",
"value": 5000000
}
] |
10-Q | 0001084991-19-000050 | 20190807105704 | 20190630 | NATURAL GAS SERVICES GROUP INC | From time to time, upon the customer’s written request, we recognize revenue when manufacturing is complete and the equipment is ready for shipment. At the customer’s request, we will bill the customer upon completing all performance obligations, but before shipment. The customer will formally request that we ship the equipment per their direction from our manufacturing facility at a later specified date and that we segregate the equipment from our finished goods, such that they are not available to fill other orders. Per the customer’s agreement change of control is passed to the customer once the equipment is complete and ready for shipment. We have operated using bill and hold agreements with certain customers for many years, with consistent satisfactory results for both the customer and us. The credit terms on these agreements are consistent with the credit terms on all other sales. All control is shouldered by the customer and there are no exceptions to the customer’s commitment to accept and pay for the manufactured equipment. Revenues recognized related to bill and hold arrangements for the six months ended June 30, 2019 was approximately $6.1 million. | [
{
"currency_/_unit": "USD",
"end_character": 1168,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 1165,
"start_date_for_period": "2019-01-01",
"value": 6100000
}
] |
10-Q | 0001628280-19-010279 | 20190807160310 | 20190630 | Teligent, Inc. | For the three months ended June 30, 2019, domestic net revenues were $13.4 million and foreign net revenues were $4.9 million. For the six months ended June 30, 2019, domestic net revenues were $23.1 million and foreign net revenues were $8.4 million. As of June 30, 2019, domestic assets were $138.4 million and foreign assets were $56.7 million. For the three months ended June 30, 2018, domestic net revenues were $11.4 million and foreign net revenues were $4.9 million. For the six months ended June 30, 2018, domestic net revenues were $21.6 million and foreign net revenues were $9.2 million. As of June 30, 2018, domestic assets were $125.9 million and foreign assets were $60.9 million. | [
{
"currency_/_unit": "USD",
"end_character": 74,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 70,
"start_date_for_period": "2019-04-01",
"value": 13400000
},
{
"currency_/_unit": "USD",
"end_character": 117,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 114,
"start_date_for_period": "2019-04-01",
"value": 4900000
},
{
"currency_/_unit": "USD",
"end_character": 199,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 195,
"start_date_for_period": "2019-01-01",
"value": 23100000
},
{
"currency_/_unit": "USD",
"end_character": 242,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 239,
"start_date_for_period": "2019-01-01",
"value": 8400000
},
{
"currency_/_unit": "USD",
"end_character": 300,
"end_date_for_period": "2019-06-30",
"label": "XBRL-OOS",
"start_character": 295,
"start_date_for_period": "2019-06-30",
"value": 138400000
},
{
"currency_/_unit": "USD",
"end_character": 338,
"end_date_for_period": "2019-06-30",
"label": "XBRL-OOS",
"start_character": 334,
"start_date_for_period": "2019-06-30",
"value": 56700000
},
{
"currency_/_unit": "USD",
"end_character": 422,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 418,
"start_date_for_period": "2018-04-01",
"value": 11400000
},
{
"currency_/_unit": "USD",
"end_character": 465,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 462,
"start_date_for_period": "2019-04-01",
"value": 4900000
},
{
"currency_/_unit": "USD",
"end_character": 548,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 544,
"start_date_for_period": "2018-01-01",
"value": 21600000
},
{
"currency_/_unit": "USD",
"end_character": 591,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 588,
"start_date_for_period": "2018-01-01",
"value": 9200000
},
{
"currency_/_unit": "USD",
"end_character": 650,
"end_date_for_period": "2018-06-30",
"label": "XBRL-OOS",
"start_character": 645,
"start_date_for_period": "2018-06-30",
"value": 125900000
},
{
"currency_/_unit": "USD",
"end_character": 688,
"end_date_for_period": "2018-06-30",
"label": "XBRL-OOS",
"start_character": 684,
"start_date_for_period": "2018-06-30",
"value": 60900000
}
] |
10-Q | 0001336917-19-000052 | 20190801165148 | 20190630 | Under Armour, Inc. | In addition to the investment in Dome, the Company has a license agreement with Dome. The Company recorded license revenues from Dome of $5.2 million and $4.8 million for the three months ended June 30, 2019 and 2018, respectively, and $11.7 million and $13.7 million for the six months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, December 31, 2018, and June 30, 2018, the Company had $5.2 million, $13.1 million, and $4.9 million, respectively, in licensing receivables outstanding, recorded in the prepaid expenses and other current assets line item within the Company's unaudited consolidated balance sheets. | [
{
"currency_/_unit": "USD",
"end_character": 141,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 138,
"start_date_for_period": "2019-04-01",
"value": 5200000
},
{
"currency_/_unit": "USD",
"end_character": 158,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 155,
"start_date_for_period": "2018-04-01",
"value": 4800000
},
{
"currency_/_unit": "USD",
"end_character": 241,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 237,
"start_date_for_period": "2019-01-01",
"value": 11700000
},
{
"currency_/_unit": "USD",
"end_character": 259,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 255,
"start_date_for_period": "2018-01-01",
"value": 13700000
},
{
"currency_/_unit": "USD",
"end_character": 410,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 407,
"start_date_for_period": "2019-04-01",
"value": 5200000
},
{
"currency_/_unit": "USD",
"end_character": 425,
"end_date_for_period": "2018-12-31",
"label": "XBRL-OOS",
"start_character": 421,
"start_date_for_period": "2018-12-31",
"value": 13100000
},
{
"currency_/_unit": "USD",
"end_character": 443,
"end_date_for_period": "2018-06-30",
"label": "XBRL-OOS",
"start_character": 440,
"start_date_for_period": "2018-06-30",
"value": 4900000
}
] |
10-Q | 0001647088-19-000036 | 20190802114535 | 20190802 | WillScot Corp | Includes $4.1 million and $2.6 million of VAPS service revenue for the three months ended June 2019 and 2018, respectively, and $7.9 million and $4.9 million of VAPS service revenue for the six months ended June 30, 2019 and 2018, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 13,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 10,
"start_date_for_period": "2018-04-01",
"value": 4099999.9999999995
},
{
"currency_/_unit": "USD",
"end_character": 30,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 27,
"start_date_for_period": "2019-04-01",
"value": 2600000
},
{
"currency_/_unit": "USD",
"end_character": 132,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 129,
"start_date_for_period": "2018-01-01",
"value": 7900000
},
{
"currency_/_unit": "USD",
"end_character": 149,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 146,
"start_date_for_period": "2019-01-01",
"value": 4900000
}
] |
10-Q | 0001125345-19-000098 | 20190731160959 | 20190630 | MACROGENICS INC | The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte’s clinical needs of MGA012. The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the clinical supply of MGA012. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. During the three months ended June 30, 2019 and 2018, the Company recognized revenue of $4.2 million and $9.9 million, respectively, for services performed under this agreement. The Company recognized revenue of $8.2 million and $9.9 million for services performed under this agreement during the six months ended June 30, 2019 and 2018, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 825,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 822,
"start_date_for_period": "2019-04-01",
"value": 4200000
},
{
"currency_/_unit": "USD",
"end_character": 842,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 839,
"start_date_for_period": "2018-04-01",
"value": 9900000
},
{
"currency_/_unit": "USD",
"end_character": 949,
"end_date_for_period": "2019-06-30",
"label": "revenues",
"start_character": 946,
"start_date_for_period": "2019-01-01",
"value": 8199999.999999999
},
{
"currency_/_unit": "USD",
"end_character": 966,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 963,
"start_date_for_period": "2018-04-01",
"value": 9900000
}
] |
10-Q | 0001125345-19-000098 | 20190731160959 | 20190630 | MACROGENICS INC | Revenue associated with each performance obligation was recognized as the research and development services were provided using a cost-based input method according to research and development costs incurred to date compared to estimated total research and development costs. The transfer of control occurred over this time period and, in management’s judgment, was the best measure of progress towards satisfying the performance obligation. All revenue related to the upfront payment was recognized by December 31, 2018. The Company recognized no revenue during the three and six months ended June 30, 2019 related to the upfront payment, and recognized $0.4 million and $0.9 million in revenue during the three and six months ended June 30, 2018, respectively, related to the transaction price allocated to the MGD007 option. No revenue was deferred at December 31, 2018 or June 30, 2019. | [
{
"currency_/_unit": "USD",
"end_character": 660,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 657,
"start_date_for_period": "2018-04-01",
"value": 400000
},
{
"currency_/_unit": "USD",
"end_character": 677,
"end_date_for_period": "2018-06-30",
"label": "revenues",
"start_character": 674,
"start_date_for_period": "2018-01-01",
"value": 900000
}
] |
10-Q | 0001125920-19-000022 | 20190807171756 | 20190630 | SHUTTERFLY INC | With respect to the convertible senior notes issued in 2013 and settled in cash upon their maturity in May 2018, the weighted-average impact to dilution for the period that the conversion option was outstanding was 660,000 shares and 690,000 shares for the three and six months ended June 30, 2018, respectively. The potential conversion impact | [
{
"currency_/_unit": "shares",
"end_character": 222,
"end_date_for_period": "2018-06-30",
"label": "eps",
"start_character": 215,
"start_date_for_period": "2018-04-01",
"value": 660000
},
{
"currency_/_unit": "shares",
"end_character": 241,
"end_date_for_period": "2018-06-30",
"label": "eps",
"start_character": 234,
"start_date_for_period": "2018-01-01",
"value": 690000
}
] |
10-Q | 0000930420-19-000238 | 20191031165804 | 20190930 | KFORCE INC | Basic earnings per share is computed as net income divided by the weighted average number of common shares outstanding (“WASO”) during the period. WASO excludes unvested shares of restricted stock. Diluted earnings per share is computed by dividing net income by diluted WASO. Diluted WASO includes the dilutive effect of potentially dilutive securities such as unvested shares of restricted stock using the treasury stock method, except where the effect of including potential common shares would be anti-dilutive. For the three and nine months ended September 30, 2019, 572 thousand and 555 thousand common stock equivalents were included in the diluted WASO, respectively. For the three and nine months ended September 30, 2018, 635 thousand and 505 thousand common stock equivalents were included in the diluted WASO, respectively. For the three and nine months ended September 30, 2019 and 2018, there were insignificant anti-dilutive common stock equivalents. | [
{
"currency_/_unit": "shares",
"end_character": 575,
"end_date_for_period": "2019-09-30",
"label": "eps",
"start_character": 572,
"start_date_for_period": "2019-07-01",
"value": 572000
},
{
"currency_/_unit": "shares",
"end_character": 592,
"end_date_for_period": "2019-09-30",
"label": "eps",
"start_character": 589,
"start_date_for_period": "2019-01-01",
"value": 555000
},
{
"currency_/_unit": "shares",
"end_character": 735,
"end_date_for_period": "2018-09-30",
"label": "eps",
"start_character": 732,
"start_date_for_period": "2018-07-01",
"value": 635000
},
{
"currency_/_unit": "shares",
"end_character": 752,
"end_date_for_period": "2018-09-30",
"label": "eps",
"start_character": 749,
"start_date_for_period": "2018-01-01",
"value": 505000
}
] |
10-Q | 0001596783-19-000205 | 20191105083839 | 20190930 | Catalent, Inc. | The Company recorded a benefit for income taxes for the three months ended September 30, 2019 of $6.9 million relative to losses from operations before income taxes of $6.8 million. The amount of this benefit is primarily driven by U.S. income tax deductions, also referred to as a windfall benefit, related to the Company’s equity compensation expense. The Company recorded a provision for income taxes for the three months ended September 30, 2018 of $1.0 million relative to losses from operations before income taxes of $13.4 million. | [
{
"currency_/_unit": "USD",
"end_character": 101,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 98,
"start_date_for_period": "2019-07-01",
"value": -6900000
},
{
"currency_/_unit": "USD",
"end_character": 172,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 169,
"start_date_for_period": "2019-07-01",
"value": -6800000
},
{
"currency_/_unit": "USD",
"end_character": 457,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 454,
"start_date_for_period": "2018-07-01",
"value": 1000000
},
{
"currency_/_unit": "USD",
"end_character": 529,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 525,
"start_date_for_period": "2018-07-01",
"value": -13400000
}
] |
10-Q | 0000005272-19-000054 | 20191101101451 | 20190930 | AMERICAN INTERNATIONAL GROUP INC | 138 million, respectively, and decreased Income from continuing operations before income tax expense by $ | [
{
"currency_/_unit": "USD",
"end_character": 3,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 0,
"start_date_for_period": "2019-01-01",
"value": -138000000
}
] |
10-Q | 0000005272-19-000054 | 20191101101451 | 20190930 | AMERICAN INTERNATIONAL GROUP INC | 170 million, respectively. The out of period adjustments for the three-month period are primarily related to increases in policyholder benefits and losses incurred reflecting updated actuarial assumptions. | [
{
"currency_/_unit": "USD",
"end_character": 3,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 0,
"start_date_for_period": "2019-01-01",
"value": -170000000
}
] |
10-Q | 0001654151-19-000004 | 20191104171603 | 20190930 | Deciphera Pharmaceuticals, Inc. | The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has incurred recurring losses including net losses of $125.0 million and $99.9 million for the nine months ended September 30, 2019 and the year ended December 31, 2018, respectively. As of September 30, 2019, the Company had an accumulated deficit of $420.8 million. The Company expects to continue to generate operating losses in the foreseeable future. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses, capital expenditure requirements and debt service payments through at least 12 months from the issuance date of these consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to fund its operations. | [
{
"currency_/_unit": "USD",
"end_character": 311,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 306,
"start_date_for_period": "2019-01-01",
"value": -125000000
},
{
"currency_/_unit": "USD",
"end_character": 329,
"end_date_for_period": "2018-12-31",
"label": "earnings",
"start_character": 325,
"start_date_for_period": "2018-01-01",
"value": -99900000
},
{
"currency_/_unit": "USD",
"end_character": 509,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 504,
"start_date_for_period": "2019-09-30",
"value": -420800000
}
] |
10-Q | 0001654948-19-000062 | 20191113185917 | 20190930 | Hartman vREIT XXI, Inc. | For the three months ended September 30, 2019 and 2018, the Company had net loss of $539,544 and $592,719, respectively. For the nine months ended September 30, 2019 and 2018, the Company incurred a net loss of $1,447,359 and $959,054, respectively. The Company does not anticipate forming any taxable REIT subsidiaries or otherwise generating future taxable income which may be offset by the net loss carry forward. The Company considers that any deferred tax benefit and corresponding deferred tax asset which may be recorded in light of the net loss carry forward would be properly offset by an equal valuation allowance in that no future taxable income is expected. Accordingly, no deferred tax benefit or deferred tax asset has been recorded in the consolidated financial statements. | [
{
"currency_/_unit": "USD",
"end_character": 92,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 85,
"start_date_for_period": "2019-07-01",
"value": -539544
},
{
"currency_/_unit": "USD",
"end_character": 105,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 98,
"start_date_for_period": "2018-07-01",
"value": -592719
},
{
"currency_/_unit": "USD",
"end_character": 222,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 213,
"start_date_for_period": "2019-01-01",
"value": -1447359
},
{
"currency_/_unit": "USD",
"end_character": 235,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 228,
"start_date_for_period": "2018-01-01",
"value": -959054
}
] |
10-Q | 0001628280-19-012816 | 20191030161320 | 20190930 | Kaleido Biosciences, Inc. | During the nine months ended September 30, 2019, operating activities used $60,149 of cash, due to our net loss of $66,819, partially offset by non-cash charges of $8,586 and net cash used by changes in our operating assets and liabilities of $1,916. Net cash provided by changes in our operating assets and liabilities primarily consisted of a $1,660 decrease in prepaid expenses and other assets and a $256 decrease in accounts payable and accrued expenses. | [
{
"currency_/_unit": "USD",
"end_character": 82,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 76,
"start_date_for_period": "2019-01-01",
"value": -60149000
},
{
"currency_/_unit": "USD",
"end_character": 122,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 116,
"start_date_for_period": "2019-01-01",
"value": -66819000
}
] |
10-Q | 0001628280-19-012816 | 20191030161320 | 20190930 | Kaleido Biosciences, Inc. | We are a clinical stage healthcare company with a limited operating history. Investment in product development in the healthcare industry, including of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval, as necessary, and become commercially viable. Our lead product candidates are currently in clinical development. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception in 2015. For the year ended December 31, 2018 and the nine months ended September 30, 2019, we reported net losses of $61,744 and $66,819, respectively. As of September 30, 2019, we had an accumulated deficit of $173,047. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates. We anticipate that our expenses will increase substantially if, and as, we: | [
{
"currency_/_unit": "USD",
"end_character": 993,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 987,
"start_date_for_period": "2019-01-01",
"value": -66819000
}
] |
10-Q | 0000109380-19-000207 | 20191105161651 | 20190930 | ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ | The Bank enters into certain lease agreements where it is the lessor of real estate. Real estate leases are made from bank-owned and subleased property to generate cash flow from the property, including from leasing vacant suites in which the Bank occupies portions of the building. Operating lease income was $3 million for both the third quarters of 2019 and 2018, and $9 million and $8 million for the first nine months of 2019 and 2018. | [
{
"currency_/_unit": "USD",
"end_character": 356,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 355,
"start_date_for_period": "2019-01-01",
"value": 9000000
},
{
"currency_/_unit": "USD",
"end_character": 365,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 364,
"start_date_for_period": "2018-01-01",
"value": 8000000
}
] |
10-Q | 0001171200-19-000351 | 20191025153545 | 20190930 | ROLLINS INC | Clark Pest
Control has a customer base of approximately 145,000 customers, which are served from 26 service locations in 2 states. Clark
Pest Control recorded revenues of approximately $139.2 million for the fiscal year ended December 31, 2018. The Company's consolidated statements of income include the results of
operations of Clark Pest Control for the period beginning April 30, 2019 through September 30, 2019. | [
{
"currency_/_unit": "USD",
"end_character": 191,
"end_date_for_period": "2018-12-31",
"label": "revenues",
"start_character": 186,
"start_date_for_period": "2018-01-01",
"value": 139200000
}
] |
10-Q | 0001084991-19-000060 | 20191108160356 | 20190930 | NATURAL GAS SERVICES GROUP INC | From time to time, upon the customer’s written request, we recognize revenue when manufacturing is complete and the equipment is ready for shipment. At the customer’s request, we will bill the customer upon completing all performance obligations, but before shipment. The customer will formally request that we ship the equipment per their direction from our manufacturing facility at a later specified date and that we segregate the equipment from our finished goods, such that they are not available to fill other orders. Per the customer’s agreement change of control is passed to the customer once the equipment is complete and ready for shipment. We have operated using bill and hold agreements with certain customers for many years, with consistent satisfactory results for both the customer and us. The credit terms on these agreements are consistent with the credit terms on all other sales. All control is shouldered by the customer and there are no exceptions to the customer’s commitment to accept and pay for the manufactured equipment. Revenues recognized related to bill and hold arrangements for the nine months ended September 30, 2019 was approximately $9.4 million. | [
{
"currency_/_unit": "USD",
"end_character": 1174,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 1171,
"start_date_for_period": "2019-01-01",
"value": 9400000
}
] |
10-Q | 0001610950-19-000050 | 20191030185910 | 20190930 | Syneos Health, Inc. | For the three and nine months ended September 30, 2019, the Company recorded income tax expense of $11.1 million and $43.8 million, respectively, compared to pre-tax income of $70.0 million and $84.0 million, respectively. The effective tax rate for the three and nine months ended September 30, 2019 varied from the U.S. federal statutory income tax rate of 21.0% primarily due to: (i) base erosion and anti-abuse minimum tax (“BEAT”), (ii) foreign income inclusions such as the Global Intangible Low-Taxed Income provisions, and (iii) valuation allowance change on domestic deferred tax assets. | [
{
"currency_/_unit": "USD",
"end_character": 104,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 100,
"start_date_for_period": "2019-07-01",
"value": 11100000
},
{
"currency_/_unit": "USD",
"end_character": 122,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 118,
"start_date_for_period": "2019-01-01",
"value": 43800000
},
{
"currency_/_unit": "USD",
"end_character": 181,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 177,
"start_date_for_period": "2019-07-01",
"value": 70000000
},
{
"currency_/_unit": "USD",
"end_character": 199,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 195,
"start_date_for_period": "2019-01-01",
"value": 84000000
}
] |
10-Q | 0001610950-19-000050 | 20191030185910 | 20190930 | Syneos Health, Inc. | For the three and nine months ended September 30, 2018, the Company recorded an income tax expense of $12.0 million and $19.1 million, respectively, compared to pre-tax income of $1.6 million and pre-tax loss of $2.3 million, respectively. The effective tax rate for the three and nine months ended September 30, 2018 varied from the U.S. federal statutory income tax rate of 21.0% primarily due to: (i) the recognition of unfavorable discrete adjustments related to foreign currency exchange; (ii) the geographical split of pre-tax income; and (iii) deferred expense related to hanging credits on domestic indefinite-lived intangibles. | [
{
"currency_/_unit": "USD",
"end_character": 107,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 103,
"start_date_for_period": "2018-07-01",
"value": 12000000
},
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 121,
"start_date_for_period": "2018-01-01",
"value": 19100000
},
{
"currency_/_unit": "USD",
"end_character": 183,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 180,
"start_date_for_period": "2018-07-01",
"value": 1600000
},
{
"currency_/_unit": "USD",
"end_character": 216,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 213,
"start_date_for_period": "2018-01-01",
"value": -2300000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | The year over year Net Sales and Loss from Operations impact for Letica Foodservice, PFP and Artistic acquisitions were $96.0 million and $8.3 million, respectively. | [
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 121,
"start_date_for_period": "2019-01-01",
"value": 96000000
},
{
"currency_/_unit": "USD",
"end_character": 142,
"end_date_for_period": "2019-09-30",
"label": "ebit",
"start_character": 139,
"start_date_for_period": "2019-01-01",
"value": -8300000.000000001
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | Net Sales for the three months ended September 30, 2019, increased $49.8 million or 3.3% to $1,581.6 million from $1,531.8 million for the three months ended September 30, 2018, due to higher selling prices, volume growth, and the Artistic and 2018 Acquisitions discussed below, partially offset by unfavorable foreign currency exchange rates. | [
{
"currency_/_unit": "USD",
"end_character": 100,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 93,
"start_date_for_period": "2019-07-01",
"value": 1581600000
},
{
"currency_/_unit": "USD",
"end_character": 122,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 115,
"start_date_for_period": "2018-07-01",
"value": 1531800000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | Income from Operations for the three months ended September 30, 2019 decreased $43.7 million or 26.2% to $122.9 million from $166.6 million for the three months ended September 30, 2018 due to the gain on sale of assets in 2018, lower net performance, higher inflation and unfavorable foreign currency exchange rates, partially offset by the higher selling prices. | [
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2019-09-30",
"label": "ebit",
"start_character": 106,
"start_date_for_period": "2019-07-01",
"value": 122900000
},
{
"currency_/_unit": "USD",
"end_character": 131,
"end_date_for_period": "2018-09-30",
"label": "ebit",
"start_character": 126,
"start_date_for_period": "2018-07-01",
"value": 166600000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | The Company’s Net Sales for the three months ended September 30, 2019 increased by $49.8 million or 3.3% to $1,581.6 million from $1,531.8 million for the three months ended September 30, 2018, due to Net Sales of $34.7 million from the Artistic and 2018 Acquisitions, higher selling prices and volume growth. These increases were offset by unfavorable foreign currency exchange rates, primarily the Euro, British Pound and Australian dollar. The higher selling prices are the results of announced price increases which benefit from inflationary pass throughs in the converting business as well as open market sales. Core converting volumes were up, primarily in global beverage volumes offset by declines in dry and frozen foods and away from home, including cups. | [
{
"currency_/_unit": "USD",
"end_character": 116,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 109,
"start_date_for_period": "2019-07-01",
"value": 1581600000
},
{
"currency_/_unit": "USD",
"end_character": 138,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 131,
"start_date_for_period": "2018-07-01",
"value": 1531800000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | Income from Operations for the three months ended September 30, 2019 decreased $43.7 million or 26.2% to $122.9 million from $166.6 million for the three months ended September 30, 2018 due to the 2018 gain of $37.1 million from the sale of the Santa Clara mill site, higher inflation, start-up costs associated with the Monroe, LA folding carton facility, costs related to a mill maintenance outage, increased incentive costs and unfavorable foreign currency exchange rate. These decreases were partially offset by the higher selling prices, cost savings through continuous improvement programs, benefits from completed capital projects and synergies. Inflation for the three months ended September 30, 2019 increased due to labor and benefit costs ($10.6 million), wood ($9.9 million), and external board ($3.0 million), partially offset by lower secondary fiber cost ($3.5 million) and other costs ($0.4 million). | [
{
"currency_/_unit": "USD",
"end_character": 111,
"end_date_for_period": "2019-09-30",
"label": "ebit",
"start_character": 106,
"start_date_for_period": "2019-07-01",
"value": 122900000
},
{
"currency_/_unit": "USD",
"end_character": 131,
"end_date_for_period": "2018-09-30",
"label": "ebit",
"start_character": 126,
"start_date_for_period": "2018-07-01",
"value": 166600000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | During the three months ended September 30, 2019, the Company recognized Income Tax Expense of $3.6 million on Income before Income Taxes and Equity Income of Unconsolidated Entity of $87.0 million. The Company is classified as a disregarded entity for U.S. income tax purposes and is generally not subject to domestic income tax expense. As a result, the consolidated financial statements exclude the tax effect of domestic earnings with the exception of state income tax for certain states that directly tax the operations of disregarded entities. The consolidated financial statements include the local country tax effect of foreign earnings generated by the Company’s wholly-owned international subsidiaries. | [
{
"currency_/_unit": "USD",
"end_character": 99,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 96,
"start_date_for_period": "2019-07-01",
"value": 3600000
},
{
"currency_/_unit": "USD",
"end_character": 189,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 185,
"start_date_for_period": "2019-07-01",
"value": 87000000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | During the three months ended September 30, 2018, the Company recognized Income Tax Expense of $4.6 million on Income before Income Taxes and Equity Income of Unconsolidated Entity of $139.7 million. | [
{
"currency_/_unit": "USD",
"end_character": 99,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 96,
"start_date_for_period": "2018-07-01",
"value": 4600000
},
{
"currency_/_unit": "USD",
"end_character": 190,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 185,
"start_date_for_period": "2018-07-01",
"value": 139700000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | The Company’s Net Sales for the nine months ended September 30, 2019 increased by $120.2 million or 2.7% to $4,640.3 million from $4,520.1 million for the nine months ended September 30, 2018, due to higher selling prices and Net Sales of $96.0 million from the Artistic and 2018 Acquisitions. These increases were partially offset by lower converting and open market volume and unfavorable foreign currency exchange rates, primarily the Euro, British Pound and Australian dollar. The higher selling prices are the results of announced price increases which benefit from inflationary pass throughs in the converting business as well as open market sales. Core converting volumes were down, primarily in dry and frozen foods, away from home, including cups, and cereal, partially offset by higher global beverage volumes and new product introductions. | [
{
"currency_/_unit": "USD",
"end_character": 116,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 109,
"start_date_for_period": "2019-01-01",
"value": 4640300000
},
{
"currency_/_unit": "USD",
"end_character": 138,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 131,
"start_date_for_period": "2018-01-01",
"value": 4520100000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | Income from Operations for the nine months ended September 30, 2019 increased $33.6 million or 9.1% to $401.5 million from $367.9 million for the nine months ended September 30, 2018 due to the higher selling prices, cost savings through continuous improvement programs, benefits from completed capital projects and synergies and lower expenses related to acquisition and integration activities. These increases were partially offset by higher inflation, start-up costs associated with the Monroe, LA folding carton facility, the gain on the sale of Santa Clara in 2018, increased incentive costs and unfavorable foreign currency exchange rates. Inflation for the nine months ended September 30, 2019 increased primarily due to wood ($37.4 million), labor and benefit costs ($29.9 million), external board ($9.9 million), and other costs, net ($2.6 million), partially offset by lower secondary fiber cost ($6.5 million). | [
{
"currency_/_unit": "USD",
"end_character": 109,
"end_date_for_period": "2019-09-30",
"label": "ebit",
"start_character": 104,
"start_date_for_period": "2019-01-01",
"value": 401500000
},
{
"currency_/_unit": "USD",
"end_character": 129,
"end_date_for_period": "2018-09-30",
"label": "ebit",
"start_character": 124,
"start_date_for_period": "2018-01-01",
"value": 367900000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | During the nine months ended September 30, 2019, the Company recognized Income Tax Expense of $12.3 million on Income before Income Taxes and Equity Income of Unconsolidated Entity of $295.0 million. The Company is classified as a disregarded entity for U.S. income tax purposes and is generally not subject to domestic income tax expense. As a result, the consolidated financial statements exclude the tax effect of domestic earnings with the exception of state income tax for certain states that directly tax the operations of disregarded entities. The consolidated financial statements include the local country tax effect of foreign earnings generated by the Company’s wholly-owned international subsidiaries. | [
{
"currency_/_unit": "USD",
"end_character": 99,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 95,
"start_date_for_period": "2019-01-01",
"value": 12300000
},
{
"currency_/_unit": "USD",
"end_character": 190,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 185,
"start_date_for_period": "2019-01-01",
"value": 295000000
}
] |
10-Q | 0001005011-19-000018 | 20191022145005 | 20190930 | GRAPHIC PACKAGING INTERNATIONAL, LLC | During the nine months ended September 30, 2018, the Company recognized Income Tax Expense of $10.4 million on Income before Income Taxes and Equity Income of Unconsolidated Entity of $288.3 million. | [
{
"currency_/_unit": "USD",
"end_character": 99,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 95,
"start_date_for_period": "2018-01-01",
"value": 10400000
},
{
"currency_/_unit": "USD",
"end_character": 190,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 185,
"start_date_for_period": "2018-01-01",
"value": 288300000
}
] |
10-Q | 0001548187-19-000006 | 20191107162826 | 20190930 | Soliton, Inc. | For the three and nine months ended September 30, 2019 and 2018, the Company incurred net losses of $4,294,897 and $2,978,621, respectively, and $10,476,776 and $6,895,374, respectively, and for the nine months ended September 30, 2019 and 2018, had net cash flows used in operating activities of $9,033,513 and $3,726,305, respectively. At September 30, 2019, | [
{
"currency_/_unit": "USD",
"end_character": 110,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 101,
"start_date_for_period": "2019-07-01",
"value": -4294897
},
{
"currency_/_unit": "USD",
"end_character": 125,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 116,
"start_date_for_period": "2018-07-01",
"value": -2978621
},
{
"currency_/_unit": "USD",
"end_character": 156,
"end_date_for_period": "2019-09-30",
"label": "earnings",
"start_character": 146,
"start_date_for_period": "2019-01-01",
"value": -10476776
},
{
"currency_/_unit": "USD",
"end_character": 171,
"end_date_for_period": "2018-09-30",
"label": "earnings",
"start_character": 162,
"start_date_for_period": "2018-01-01",
"value": -6895374
},
{
"currency_/_unit": "USD",
"end_character": 307,
"end_date_for_period": "2019-09-30",
"label": "XBRL-OOS",
"start_character": 298,
"start_date_for_period": "2019-01-01",
"value": -9033513
},
{
"currency_/_unit": "USD",
"end_character": 322,
"end_date_for_period": "2018-09-30",
"label": "XBRL-OOS",
"start_character": 313,
"start_date_for_period": "2018-01-01",
"value": -3726305
}
] |
10-Q | 0001094285-19-000162 | 20191025195204 | 20190929 | TELEDYNE TECHNOLOGIES INC | Selling, general and administrative expenses, including research and development and bid and proposal expense, increased $12.2 million in the third quarter of 2019 and primarily reflected the impact of higher sales. Selling, general and administrative expenses for the third quarter of 2019, as a percentage of net sales decreased slightly to 23.2% from 23.9%. Corporate expense, which is included in selling, general and administrative expenses, was $14.6 million for the third quarter of 2019, compared | [
{
"currency_/_unit": "USD",
"end_character": 458,
"end_date_for_period": "2019-09-29",
"label": "ebit",
"start_character": 454,
"start_date_for_period": "2019-07-01",
"value": -14600000
}
] |
10-Q | 0001062993-19-004184 | 20191106164805 | 20190928 | SunOpta Inc. | (4) Comprises fruit snack offerings, as well as the sale of flexible resealable pouch and nutrition bar products in the third quarter and first three quarters of 2018 of $0.0 million and $3.1 million, respectively. The Company exited the flexible resealable pouch and nutrition bar product lines and operations in the fourth quarter of 2017 but continued to deliver remaining inventories to customers during 2018. | [
{
"currency_/_unit": "USD",
"end_character": 175,
"end_date_for_period": "2018-09-29",
"label": "revenues",
"start_character": 171,
"start_date_for_period": "2018-07-01",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 191,
"end_date_for_period": "2018-09-29",
"label": "revenues",
"start_character": 188,
"start_date_for_period": "2017-12-31",
"value": 3100000
}
] |
10-Q | 0001062993-19-004184 | 20191106164805 | 20190928 | SunOpta Inc. | (4) Comprises fruit snack offerings, as well as the sale of flexible resealable pouch and nutrition bar products in the third quarter and first three quarters of 2018 of $0.0 million and $3.1 million, respectively. The Company exited the flexible resealable pouch and nutrition bar product lines and operations in the fourth quarter of 2017 but continued to deliver remaining inventories to customers during 2018. | [
{
"currency_/_unit": "USD",
"end_character": 175,
"end_date_for_period": "2018-09-29",
"label": "revenues",
"start_character": 171,
"start_date_for_period": "2018-07-01",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 191,
"end_date_for_period": "2018-09-29",
"label": "revenues",
"start_character": 188,
"start_date_for_period": "2017-12-31",
"value": 3100000
}
] |
10-Q | 0001125345-19-000112 | 20191106160806 | 20190930 | MACROGENICS INC | The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized over the period from the effective date of the agreement until such time as the clinical activities were transferred to Incyte using an input method according to research and development costs incurred to date compared to estimated total research and development costs. These clinical activities were substantially completed as of June 30, 2018. During the three months ended September 30, 2019 and 2018, the Company recognized no revenue and revenue of $10.5 million, respectively, under the Incyte Agreement. The Company recognized revenue of $0.1 million and $13.6 million under the Incyte Agreement during the nine months ended September 30, 2019 and 2018, respectively. Revenue recognized during the three and nine months ended September 30, 2018 included $10.0 million in development milestones. | [
{
"currency_/_unit": "USD",
"end_character": 33,
"end_date_for_period": "2017-10-31",
"label": "revenues",
"start_character": 28,
"start_date_for_period": "2017-10-01",
"value": 150000000
},
{
"currency_/_unit": "USD",
"end_character": 168,
"end_date_for_period": "2017-10-31",
"label": "XBRL-OOS",
"start_character": 165,
"start_date_for_period": "2017-10-01",
"value": 4000000
},
{
"currency_/_unit": "USD",
"end_character": 661,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 659,
"start_date_for_period": "2019-07-01",
"value": 0
},
{
"currency_/_unit": "USD",
"end_character": 690,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 686,
"start_date_for_period": "2018-07-01",
"value": 10500000
},
{
"currency_/_unit": "USD",
"end_character": 781,
"end_date_for_period": "2019-09-30",
"label": "revenues",
"start_character": 778,
"start_date_for_period": "2019-01-01",
"value": 100000
},
{
"currency_/_unit": "USD",
"end_character": 799,
"end_date_for_period": "2018-09-30",
"label": "revenues",
"start_character": 795,
"start_date_for_period": "2018-01-01",
"value": 13600000
}
] |
End of preview. Expand
in Dataset Viewer.
HiFi-KPI Lite: Expert-Curated Financial KPI Extraction
Dataset Summary
HiFi-KPI Lite is a manually curated subset of the HiFi-KPI dataset, designed for evaluating structured financial KPI extraction. Unlike the full HiFi-KPI dataset, HiFi-KPI Lite maps financial entities to a much reduced, expert-defined label space. The dataset consists of ∼8K paragraphs and ∼25K entities, making it suitable for rapid model evaluation.
Supported Tasks
The dataset is optimized for:
- Named Entity Recognition (NER): Identifying financial KPIs from text.
- Structured Data Extraction: Extracting numerical values, currencies, and corresponding time periods from financial statements.
- Text Classification: Associating financial statements with expert-mapped KPI labels.
Languages
The dataset is in English, sourced from SEC 10-K and 10-Q filings.
Dataset Structure
Data Fields
Each entry in HiFi-KPI Lite includes:
- form_type: "10-K" or "10-Q"
- accession_number: Unique filing identifier
- filing_date: Timestamp of the filing
- company_name: Name of the reporting entity
- text: Extracted paragraph from the filing
- entities (list of extracted entities):
- label: Expert-defined financial KPI category(Ebit, revnues ..)
- start_date_for_period / end_date_for_period: Time period of the financial figure
- currency/unit: Currency (e.g., USD, EUR)
- value: Extracted numerical figure
Dataset Statistics
| Split | # Paragraphs | # Entities |
|---|---|---|
| Train | 6,359 | 19,749 |
| Dev | 768 | 2,601 |
| Test | 856 | 2,437 |
Baseline Model Performance
We establish baselines using:
- Sequence Labeling: fine-tuning BERT (bert-base-uncased) with a token classification head.
- LLM-based Structured Extraction: Few-shot prompting for NuExtract, Qwen-2.5-14B, and DeepSeek-V3.
Macro F1 Performance on HiFi-KPI Lite
| Model | Precision | Recall | Micro F1 |
|---|---|---|---|
| BERT (SL) | 89.2 | 91.8 | 89.1 |
| Qwen-2.5-14B | 63.7 | 60.2 | 49.5 |
| DeepSeek-V3 | 67.8 | 65.9 | 46.4 |
Uses and Applications
HiFi-KPI Lite is useful for:
- Benchmarking KPI Extraction: Evaluating model performance on structured financial data extraction.
- Fine-Grained Financial NLP Tasks: Training models on structured financial entity recognition.
- Evaluation of Large Language Models (LLMs): Testing how well LLMs generalize to financial entity extraction.
Citation
If you use HiFi-KPI Lite in your research, please cite:
@article{aavang2025hifi,
title={HiFi-KPI: A Dataset for Hierarchical KPI Extraction from Earnings Filings},
author={Aavang, Rasmus and Rizzi, Giovanni and Bøggild, Rasmus and Iolov, Alexandre and Zhang, Mike and Bjerva, Johannes},
journal={arXiv preprint arXiv:2502.15411},
year={2025}
}
Access
Example code and repo with links to all models at GitHub Repository
- Downloads last month
- 78
Size of downloaded dataset files:
12.6 MB
Size of the auto-converted Parquet files:
2.3 MB
Number of rows:
7,983
Models trained or fine-tuned on AAU-NLP/hifi-kpi-lite